These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

378 related articles for article (PubMed ID: 33635141)

  • 1. Neurofilament light chain in a phase 2 clinical trial of ibudilast in progressive multiple sclerosis.
    Fox RJ; Raska P; Barro C; Karafa M; Konig V; Bermel RA; Chase M; Coffey CS; Goodman AD; Klawiter EC; Naismith RT; Kuhle J
    Mult Scler; 2021 Nov; 27(13):2014-2022. PubMed ID: 33635141
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Evaluation of cerebrospinal fluid neurofilament light chain levels in multiple sclerosis and non-demyelinating diseases of the central nervous system: clinical and biochemical perspective.
    Arslan B; Ayhan Arslan G; Tuncer A; Karabudak R; Sepici Dinçel A
    Bosn J Basic Med Sci; 2022 Sep; 22(5):699-706. PubMed ID: 35490364
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Comparison of three analytical platforms for quantification of the neurofilament light chain in blood samples: ELISA, electrochemiluminescence immunoassay and Simoa.
    Kuhle J; Barro C; Andreasson U; Derfuss T; Lindberg R; Sandelius Å; Liman V; Norgren N; Blennow K; Zetterberg H
    Clin Chem Lab Med; 2016 Oct; 54(10):1655-61. PubMed ID: 27071153
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Dimethyl fumarate decreases neurofilament light chain in CSF and blood of treatment naïve relapsing MS patients.
    Sejbaek T; Nielsen HH; Penner N; Plavina T; Mendoza JP; Martin NA; Elkjaer ML; Ravnborg MH; Illes Z
    J Neurol Neurosurg Psychiatry; 2019 Dec; 90(12):1324-1330. PubMed ID: 31611264
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Metabolomics detects clinically silent neuroinflammatory lesions earlier than neurofilament-light chain in a focal multiple sclerosis animal model.
    Yeo T; Bayuangga H; Augusto-Oliveira M; Sealey M; Claridge TDW; Tanner R; Leppert D; Palace J; Kuhle J; Probert F; Anthony DC
    J Neuroinflammation; 2022 Oct; 19(1):252. PubMed ID: 36210459
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Ultrasensitive immunoassay allows measurement of serum neurofilament heavy in multiple sclerosis.
    Verberk IMW; Koel-Simmelink M; Twaalfhoven H; Vrenken H; Korth C; Killestein J; Teunissen CE; Bridel C
    Mult Scler Relat Disord; 2021 May; 50():102840. PubMed ID: 33626430
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Quantitation of neurofilament light chain protein in serum and cerebrospinal fluid from patients with multiple sclerosis using the MSD R-PLEX NfL assay.
    Ulndreaj A; Sohaei D; Thebault S; Pons-Belda OD; Fernandez-Uriarte A; Campbell C; Cheo D; Stengelin M; Sigal G; Freedman MS; Scarisbrick IA; Prassas I; Diamandis EP
    Diagnosis (Berl); 2023 Aug; 10(3):275-280. PubMed ID: 36788117
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Serum macrophage migration inhibitory factor levels predict brain atrophy in people with primary progressive multiple sclerosis.
    Ladakis DC; Reyes-Mantilla MI; Gadani SP; Mace JW; Dominguez-Penuela SC; Appiah MJ; Smith MD; Bhargava P; Fox RJ; Saidha S; Calabresi PA
    Mult Scler; 2024 Jan; 30(1):35-43. PubMed ID: 37982154
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Comparison of plasma and cerebrospinal fluid neurofilament light in a multiple sclerosis trial.
    de Flon P; Laurell K; Sundström P; Blennow K; Söderström L; Zetterberg H; Gunnarsson M; Svenningsson A
    Acta Neurol Scand; 2019 May; 139(5):462-468. PubMed ID: 30740668
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Neurofilament light and heavy subunits compared as therapeutic biomarkers in multiple sclerosis.
    Kuhle J; Malmeström C; Axelsson M; Plattner K; Yaldizli O; Derfuss T; Giovannoni G; Kappos L; Lycke J
    Acta Neurol Scand; 2013 Dec; 128(6):e33-6. PubMed ID: 23763388
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Neurofilament light levels are associated with long-term outcomes in multiple sclerosis.
    Kuhle J; Plavina T; Barro C; Disanto G; Sangurdekar D; Singh CM; de Moor C; Engle B; Kieseier BC; Fisher E; Kappos L; Rudick RA; Goyal J
    Mult Scler; 2020 Nov; 26(13):1691-1699. PubMed ID: 31680621
    [TBL] [Abstract][Full Text] [Related]  

  • 12. A pharmacokinetic and biomarker study of delayed-release dimethyl fumarate in subjects with secondary progressive multiple sclerosis: evaluation of cerebrospinal fluid penetration and the effects on exploratory biomarkers.
    Edwards KR; Kamath A; Button J; Kamath V; Mendoza JP; Zhu B; Plavina T; Woodward C; Penner N
    Mult Scler Relat Disord; 2021 Jun; 51():102861. PubMed ID: 33773271
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Ibudilast (MN-166) in amyotrophic lateral sclerosis- an open label, safety and pharmacodynamic trial.
    Babu S; Hightower BG; Chan J; Zürcher NR; Kivisäkk P; Tseng CJ; Sanders DL; Robichaud A; Banno H; Evora A; Ashokkumar A; Pothier L; Paganoni S; Chew S; Dojillo J; Matsuda K; Gudesblatt M; Berry JD; Cudkowicz ME; Hooker JM; Atassi N
    Neuroimage Clin; 2021; 30():102672. PubMed ID: 34016561
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Plasma neurofilament light chain levels in patients with MS switching from injectable therapies to fingolimod.
    Piehl F; Kockum I; Khademi M; Blennow K; Lycke J; Zetterberg H; Olsson T
    Mult Scler; 2018 Jul; 24(8):1046-1054. PubMed ID: 28627962
    [TBL] [Abstract][Full Text] [Related]  

  • 15. The relationship of cerebrospinal fluid neurofilament levels with magnetic resonance imaging lesion location and disease activity in multiple sclerosis.
    Adams A; Tilden W; Bestwick J; Holden D; Bianchi L; Smets I; Giovannoni G; Gnanapavan S
    Eur J Neurol; 2022 Sep; 29(9):2754-2760. PubMed ID: 35615966
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Establishment of neurofilament light chain Simoa assay in cerebrospinal fluid and blood.
    Hendricks R; Baker D; Brumm J; Davancaze T; Harp C; Herman A; Büdingen HV; Townsend M; Fischer SK
    Bioanalysis; 2019 Aug; 11(15):1405-1418. PubMed ID: 31401845
    [No Abstract]   [Full Text] [Related]  

  • 17. CSF inflammatory biomarkers responsive to treatment in progressive multiple sclerosis capture residual inflammation associated with axonal damage.
    Romme Christensen J; Komori M; von Essen MR; Ratzer R; Börnsen L; Bielekova B; Sellebjerg F
    Mult Scler; 2019 Jun; 25(7):937-946. PubMed ID: 29775134
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Cerebrospinal fluid neurofilament light chain in multiple sclerosis and its subtypes: a meta-analysis of case-control studies.
    Martin SJ; McGlasson S; Hunt D; Overell J
    J Neurol Neurosurg Psychiatry; 2019 Sep; 90(9):1059-1067. PubMed ID: 31123141
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Development of an age-adjusted model for blood neurofilament light chain.
    Harp C; Thanei GA; Jia X; Kuhle J; Leppert D; Schaedelin S; Benkert P; von Büdingen HC; Hendricks R; Herman A
    Ann Clin Transl Neurol; 2022 Apr; 9(4):444-453. PubMed ID: 35229997
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Microstructural and functional brain abnormalities in multiple sclerosis predicted by osteopontin and neurofilament light.
    Orsi G; Cseh T; Hayden Z; Perlaki G; Nagy SA; Giyab O; Olsen DA; Madsen JS; Berki T; Illes Z
    Mult Scler Relat Disord; 2021 Jun; 51():102923. PubMed ID: 33813096
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 19.